2023
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study
Castro D, Zengin Z, Malhotra J, Bergerot C, Meza L, Dizman N, Govindarajan A, Hsu J, Chehrazi-Raffle A, Chawla N, Mercier B, Chen S, Feng M, Prajapati S, Lee K, Philip E, Dorff T, Lyou Y, Pal S. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study. Cancer Investigation 2023, 41: 70-76. PMID: 36239609, DOI: 10.1080/07357907.2022.2136683.Peer-Reviewed Original Research
2022
Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.Peer-Reviewed Original ResearchCOVID-19 vaccinationBlood samplesSystemic treatmentAntibody titersGenitourinary malignanciesSubset of ptsImmune checkpoint inhibitorsBaseline blood samplesLong-term efficacyAdditional blood samplesCOVID-19 vaccineSARS-CoV-2Short-term effectivenessCancer ptsSerologic outcomeCheckpoint inhibitorsGenitourinary cancersMedian ageTherapy cyclesBladder cancerTCR sequencingIgG ELISACoV-2Host immunityVaccination